Advanced searches left 3/3

Carcinoma thyroid mutation - Europe PMC

Summarized by Plex Scholar
Last Updated: 16 July 2022

* If you want to update the article please login/register

Sorafenib in Metastatic Papillary Thyroid Carcinoma with BRAF K601E Mutation on Liquid Biopsy: A Case Report and Literature Review.

Differentiated thyroid cancer includes papillary and follicular carcinomas, and is the most common type of thyroid cancer. The incidence of this cancer has risen in recent years, and even if it does not respond to radioactive iodine therapy, the prognosis is even worse: the median overall survival rate for a subgroup of patients with metastasis is only 10%. Liquid biopsy can be used in a few patients to reveal genetic mutations, thus allowing for a precision medicine approach with target therapy. Use sorafenib in Papillary thyroid carcinoma as well as a rise in QoL in our case.

Source link: https://europepmc.org/article/MED/35630083


Histological and Immunohistochemical Braf V600e Mutation Detection in Papillary Thyroid Carcinoma

Background: Differentiated thyroid cancer is the most common malignant endocrine neoplasia in the world. Papillary thyroid cancer is the most common disorder and has the most aggressive prognosis. Methods: and methods Real-time PCR, immunohistochemical, and histological testing was performed in patients diagnosed with thyroid cancer between 2013 and 2016, as part of the Fundaciu00f3n Valle del Valle del Valle del Valle hospital in Cali Colombia, with the BRAF V600E mutation. Results: Samples from 18 patients with papillary thyroid carcinoma were reviewed by a real-time PCR test for the BRAF gene.

Source link: https://europepmc.org/article/PPR/PPR491279


Exploring the correlation analysis of immune microenvironment, mutation burden and prognosis of papillary thyroid carcinoma based on Estimate algorithm.

Background This research was conducted to determine the connection between immune infiltration and tumor mutation burden in papillary thyroid carcinoma. Conclusions The stromal score and immune score of papillary thyroid carcinoma tissue were lower than those of normal thyroid tissue, respectively. The progress-free survival of the low TMB group was greater than that of the high TMB group, according to the progressive-free survival of the low TMB group, which was quicker than that of the high TMB group. TMB negatively related to the immune and stromal scores of papillary thyroid carcinoma, according to TMB. Thyroid cancer gene mutations reduce immune cell infiltration and alter the thyroid cancer microenvironment. Combined immunological and genomic examination of papillary thyroid carcinoma can reveal potential prognostic markers and therapeutic goals, as well as providing insight into the tumor immune escape mechanism.

Source link: https://europepmc.org/article/MED/35694099


Integrating BRAF V600E mutation, ultrasonic and clinicopathologic characteristics for predicting the risk of cervical central lymph node metastasis in papillary thyroid carcinoma.

Background: The benefits of prophylactic central lymph node dissection for clinically node-negative patients remained a significant number of controversy. Our aim was to investigate the correlation between cervical central lymph node metastasis and BRAF V600E mutation, ultrasonic and clinicopathologic characteristics in papillary thyroid carcinoma. Methods and materials The new study included a total of 112 consecutive PTC patients who underwent thyroidectomy plus cervical central neck dissection. Both a predictive model and multivariate analysis were conducted to investigate the correlation between predictive factors and cervical CLNM in PTC patients, and later a predictive model was also developed. • U00d7 + 1. 143 1. 241 u00d7 + 1. 143 u00d7 + 1. 143 u00d7 PTC patients was determined by a risk score of cervical CLNM in PTC patients.

Source link: https://europepmc.org/article/MED/35473554


Clinicopathological Implications of the BRAF V 600 E Mutation in Papillary Thyroid Carcinoma of Ukrainian Patients Exposed to the Chernobyl Radiation in Childhood: A Study for 30 Years After the Accident.

The number of papillary thyroid carcinomas caused by the BRAF V600E oncoprotein is on the rise in patients exposed to radiation at a young age, with time since the Chernobyl crash. In PTCs from patients with internal radiation history, the BRAF V600E in PTCs from patients with internal radiation history have not been adequately investigated so far. In the BRAF V600E positive and BRAF V600E -negative PTCs from the Ukrainian patients exposed to Chernobyl radiation and treated more than 30 years since the accident, the authors examines the structural characteristics, proliferative action, surgical procedures, and dosimetric results. The study included 428 PTCs from patients aged 4-49 years at surgery who lived in Ukraine's six northern regions that were most affected by 131 I, ranging from 1990 to 2017. The VE1 antibody was used for BRAF V600E by immunohistochemical staining. In the BRAF V600E -positive PTCs, Tumor invasive characteristics were less common and did not correspond with POC level, and did not change with POC level. In the wake of this genetic disruption, BRAF V600E-positive PTCs from patients with radiogenic thyroid cancer diagnosed in a high-risk group for radiogenic thyroid cancer diagnosed in the 30 years after the Chernobyl accident did not have an elevated incidence of POC, but a more careful analysis of patients with BRAF V600E -positive tumors may be helpful to middle-aged patients with BRAF V600E -positive tumors suggestive of RAI therapy may be helpful to patients with BRAF V600E a BRAF V600E invasive PTCs from patients with a BRIC s from patients from the BFR invasive thyroid disease invasive thyroid cancer diagnosed in the BRAF VRT invasive PTC a BRAF Vogue invasive PTC invasive disease invasive tumors with RAI therapy for RAI invasive TTC invasive tumors invasive BRAF V600E invasive TTC -positive BRAF V600E-positive PTCs from BRAF V600E-positive BRAF V600E -positive PTCs with RAI -positive BRAF.

Source link: https://europepmc.org/article/MED/35665338

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions